The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
April 24th 2025
The treatment received indications as a monotherapy and in combination regimen with carboplatin or cisplatin and gemcitabine.
Early Peanut Introduction Deemed Safe to Prevent Allergy, Some Parents Unaware or Hesitant
July 26th 2023With new guidelines surrounding the introduction of peanuts to infants as young as 4 months of age, more work needs to be done to increase awareness among parents and caregivers to prevent peanut allergy at an early age.
Read More
Once-Weekly Insulin Analogue Demonstrates Promising Results for Those With Type 2 Diabetes
July 25th 2023Patients with type 2 diabetes receiving once-weekly insulin icodec were more likely to reach a hemoglobin A1C level below 7% compared to those who received once-daily insulin analogues.
Read More
Axatilimab Produces Significant Response in Patients with Fatal Post-Transplant Complication
July 25th 2023Co-developers Incyte and Syndax will submit a biologics license application to the FDA at the end of 2023 based on the results of a phase 2 trial among adult and pediatric patients with chronic graft-versus-host disease.
Read More
As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign
July 24th 2023Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.
Read More
Event-Free Survival Improved by Radiotherapy for B-Cell Lymphoma in Younger Patients
July 19th 2023Due to the assessment of computerized tomography with criteria from 1999, the role of radiotherapy in patients with diffuse large B-cell lymphoma with bulky or extranodal disease remains undefined.
Read More
Confirmatory PAPILLON Study Supports Amivantamab-vmjw For Patients with Severe Lung Cancer Mutation
July 19th 2023The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.
Read More